B2BROKER
25.1.2022 13:02:11 CET | Business Wire | Press release
B2Broker , a leading liquidity and technology provider of solutions to the Forex and financial services industry, has secured a licence from the Financial Services Commission (FSC) Mauritius , the company has announced. The licence has been acquired under the name of B2B Prime Services Limited, a member of the B2Broker Group of Companies, which as of 12th November, 2021, possesses an Investment Dealer licence (Full Service Dealer excluding underwriting /code SEC-2.1, Licence # C117017139).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005241/en/
Description of Authorised Activity
As an authorised Dealer in Securities, B2B Prime Services is permitted to act as intermediary in the execution of securities transactions for clients in accordance with the country’s local legislation. Under Mauritius regulation, the company will operate as a Prime of Prime (PoP) Multi-Asset Liquidity Provider, focusing on institutional and professional clients across the whole spectrum of the financial markets. Its core investment services consist of leveraged derivative products in CFDs (e.g. Forex, metals, commodities, shares, indices).
About the FSC
The FSC is the integrated regulator in Mauritius for the financial services sector and was established in 2001 to licence, regulate, monitor and supervise the conduct of business activities in these sectors in accordance with local legislation. The regulator is committed to the sustained development of Mauritius as a sound and competitive Financial Services Centre with the aim of promoting the development, fairness, efficiency and transparency of financial institutions and capital markets, suppressing crime and malpractices so as to provide protection to members of the public investing in non-banking financial products, and ensuring the soundness and stability of the financial system in Mauritius.
About B2Broker Group of Companies
B2Broker is a global brand with a solid reputation in the B2B sphere as one of the most in-demand technology and liquidity providers for Forex and crypto brokers, crypto exchanges and other financial services entities. The group helps these firms empower their businesses through building a successful, transparent and ethical environment and connecting them to the markets in a short space of time and at a reasonable cost.
B2Broker offers a broad range of services including Crypto/Forex/CFD liquidity, Crypto/Forex Broker turnkey solutions, crypto payment processing (B2BinPay), MT4/5 white label solutions, B2Core (Trader’s Room) , B2Trader (Matching Engine) and liquidity on over 800 trading instruments across the entire spectrum of assets.
Headquartered in Moscow, B2Broker has several years of operational experience with 10 offices in 8 countries across Russia, Europe, Asia and MENA. A total of 7 licences so far to its name including FCA, AEMI, Central Bank of Russia, and now FSC, allows B2Broker to serve clients across more than 50 countries, offering Forex liquidity distribution and a range of other services to the Forex, Crypto and Securities industries. The company has secured a large portfolio of well-known global clients in the financial services industry with plans to further increase company representation and visibility across the globe.
CEO and Founder of B2Broker Group, Arthur Azizov, commented, “We are pleased to have added another prestigious licence to our growing portfolio. The licence ensures the reliability and transparency of all operations in accordance with the strict supervision of the FSC and adds further credibility to us as a leading global fintech player. Industry regulation is undoubtedly the best way to achieve total legitimisation of the Forex and financial services industry and our latest licence acquisition means that even more clients across the world will be able to benefit from the highest level of protection offered by one of the world’s leading, multi-regulated technology and liquidity providers.”
The acquisition of the latest FSC licence broadens B2Broker’s horizons enabling the company to secure further business in its quest to expand its global reach. Aside from this latest licence acquisition, the company currently has several other licence applications with established regulators in process which are expected to be concluded during 2022.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005241/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom